For example, there is evidence that glucocorticoids promote PCa progression in patients whose tumors express GR, and that men who receive glucocorticoids concomitantly with the second-line ADT drug enzalutamide have worse overall survival5,7. The gene discussed is NR3C1; the disease is posterior cortical atrophy.